Synergic Effect of -Mangostin on the Cytotoxicity of Cisplatin in a Cervical Cancer Model.

Cervical cancer is the second leading cause of death among Mexican women. The treatment with cis-diamminedichloroplatinum (II) (CDDP) has some serious side effects. -mangostin (-M), has a protective effect against CDDP-induced nephrotoxicity, as well as antioxidant, antitumor, and anti-inflammatory properties. Hence, we explored the in vitro and in vivo effect of -M on human cervical cancer cell proliferation when combined with CDDP. In vitro, The cytotoxic effect of -M and/or CDDP was measured by the 3-(3,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium assay. Meanwhile, apoptosis, reactive oxygen species (ROS) production, and the cell cycle were determined with flow cytometry. For -M+CDDP treatment, both a coincubation and preincubation scheme were employed. In vivo, xenotransplantation was performed in female athymic BALB/c (nu/nu) mice, and then tumor volume and body weight were measured weekly, whereas -M interfered with the antiproliferative activity of CDDP in the coincubation scheme, with preincubation with -M+CDDP showing significantly greater cytotoxicity than CDDP or -M alone, significantly inhibiting average tumor volume and preventing nephrotoxicity. This effect was accompanied by increased apoptosis and ROS production by HeLa cervical cancer cells, as well as an arrest in the cell cycle. These results suggest that -M may be useful as a neoadjuvant agent in cervical cancer therapy.